Ac Immune SA 6-K Filing
Ticker: ACIU · Form: 6-K · Filed: Apr 7, 2026 · CIK: 0001651625
| Field | Detail |
|---|---|
| Company | Ac Immune SA (ACIU) |
| Form Type | 6-K |
| Filed Date | Apr 7, 2026 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Ac Immune SA (ticker: ACIU) to the SEC on Apr 7, 2026.
How long is this filing?
Ac Immune SA's 6-K filing is 1 pages with approximately 369 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 369 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2026-04-07 07:33:58
Filing Documents
- dp244548_6k.htm (6-K) — 10KB
- dp244548_ex9901.htm (EX-99.1) — 12KB
- image_001.jpg (GRAPHIC) — 2KB
- 0000950103-26-005409.txt ( ) — 27KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On April 7, 2026, AC Immune SA (“AC Immune”) issued a press release announcing an agreement with Eli Lilly and Company to amend their license and collaboration agreement dated as of December 11, 2018, as amended (the “License Agreement”), to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases (the “Amendment”). Pursuant to the Amendment, AC Immune will receive a CHF 10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment to the License Agreement dated as of March 20, 2020. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF 1.7 billion, plus tiered percentage royalty payments in the low double digits, as previously disclosed. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K. The descriptions of the Amendment in this Report on Form 6-K and in the accompanying Exhibit 99.1 are not complete and are qualified in their entirety by reference to the full text of such Amendment, a copy of which will be filed as an exhibit to a future filing by AC Immune with the U.S. Securities and Exchange Commission. EXHIBIT INDEX Exhibit Number Description 99.1 Press Release, dated April 7, 2026 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: April 7, 2026